---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-011047"
form_type: "8-K"
ticker: "CAPR"
cik: "0001133869"
company_name: "CAPRICOR THERAPEUTICS, INC."
filed_at: "2025-08-11T23:59:59+00:00"
generated_at: "2026-05-17T15:10:34.713129+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Capricor Q2 net loss $25.9M; FDA accepts all PLI observations; StealthX vaccine enters clinic

## Summary
- Net loss of $25.9M ($0.57 per share) for Q2 2025 vs $11.0M ($0.35) in Q2 2024; revenue $0 vs $4.0M.
- Cash, equivalents and securities $122.8M at June 30, 2025; expected to fund operations into Q4 2026.
- FDA accepted all 483 observations from Pre-License Inspection; Type A meeting scheduled for August 2025 to discuss Deramiocel BLA resubmission.
- FDA cleared IND for StealthX exosome-based vaccine; NIAID-initiated Phase 1 trial initiated in August 2025; first dosing imminent.
- HOPE-3 Phase 3 topline data expected Q4 2025; Orphan Drug Designation granted for Deramiocel in Becker muscular dystrophy.

## SEC filing metadata
- accession: 0001558370-25-011047
- form_type: 8-K
- ticker: CAPR
- cik: 0001133869
- company_name: CAPRICOR THERAPEUTICS, INC.
- filed_at: 2025-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1133869/000155837025011047/0001558370-25-011047-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1133869/000155837025011047/capr-20250811x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-011047
- JSON: https://secwatch.observer/filing/0001558370-25-011047.json
- Plain text: https://secwatch.observer/filing/0001558370-25-011047.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.